Switzerland· 69300001
Truqap 160 mg, Filmtabletten
A capivasertib product containing capivasertibum, registered in Switzerland by AstraZeneca AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Capivasertib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX27 (capivasertib), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Capivasertib · ATC L01EX27
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of capivasertib costs, country by country.
Normalised to the WHO defined daily dose (0.46 g), so markets compare like for like.
- Switzerland: $320.95 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Capivasertib · price per daily dose (0.46 g)
USD · FX 28 Sept 2026
- CH Switzerland$320.95
The record
At a glance
Swissmedic (Switzerland)- Active substance
- capivasertibum
- Manufacturer
- AstraZeneca AG
- Country
- Switzerland (CH)
- ATC code
- L01EX27
- ATC class
- Capivasertib
- Defined daily dose
- 0.46 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680693000018Blist 4 x 16 StkCHF 5925.3
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Capivasertib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTRUQAPAstraZeneca Pharmaceuticals LP
- CzechiaTRUQAPAstraZeneca AB, Södertälje
- SpainTRUQAP 160 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- FinlandTRUQAPAstraZeneca AB
- IrelandTRUQAP 160 mg film-coated tabletsAstraZeneca AB
- BelgiumTruqap 160 mgAstraZeneca
- NetherlandsTRUQAP 160 mg filmomhulde tablettenAstraZeneca AB
- NorwayTruqapAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Truqap
- Liechtenstein · Truqap
- Norway · Truqap
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/72352c13-21a0-408d-96d4-a79f218a965a GET /v1/drugs/72352c13-21a0-408d-96d4-a79f218a965a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "capivasertibum 160 mg",
"valid_from": "2025-05-01",
"limitations": "[{\"description\":\"Zur Behandlung ausschliesslich in Kombination mit Fulvestrant von erwachsenen Patientinnen mit hormonrezeptor(HR-)positivem, humanen epidermalen Wachstumsfaktor-Rezeptor 2 (HER2) negativem lokal fortgeschrittenem oder metastasiertem Brustkrebs mit einer oder mehreren PIK3CA/AKT1/PTEN-Alterationen nach Rezidiv oder Progression unter oder nach einer endokrinbasierten Therapie. Folgende Kriterien müssen erfüllt sein:<br>\\n-\\tNicht mehr als 2 Vortherapien im fortgeschrittenem Brustkrebs-Stadium mit einer endokrinen Therapie<br>\\n-\\tNicht mehr als 1 Vortherapie im fortgeschrittenem Brustkrebs-Stadium mit einer Chemotherapie<br>\\n-\\tKeine Vorbehandlung mit einem AKT-, Pl3K- oder mTOR-lnhibitor<br>\\n-\\tKein Einsatz bei viszeraler Krise<br>\\n<br>\\nDie Patientinnen dürfen maximal bis zur Progression der Erkrankung behandelt werden.<br>\\n<br>\\nDie AstraZeneca AG erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung TRUQAP einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21727.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21727.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-05-01\",\"validTo\":\"2027-04-30\"}]",
"galenic_form": "Filmtabl 160 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2025-05-01",
"self_retention_pct": 10
}See everything about capivasertib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.